Citadel Advisors
CATX icon

Citadel Advisors’s Perspective Therapeutics CATX Stock Holding History

Citadel Advisors’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$263K Buy
63,000
+8,000
+15% +$33.8K ﹤0.01% 10781
2025
Q4 		$151K Buy
55,000
+41,900
+320% +$120K ﹤0.01% 11310
2025
Q3 		$44.9K Sell
13,100
-4,300
-25% -$15.7K ﹤0.01% 12252
2025
Q2 		$59.9K Buy
17,400
+5,200
+43% +$13.7K ﹤0.01% 11679
2025
Q1 		$26K Sell
12,200
-32,800
-73% -$98.4K ﹤0.01% 12938
2024
Q4 		$144K Buy
45,000
+43,100
+2,268% +$352K ﹤0.01% 10958
2024
Q3 		$25.4K Buy
+1,900
New +$25.3K ﹤0.01% 12587

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors's CATX Position: Q1 2026 in Review

Citadel Advisors increased its Perspective Therapeutics (CATX) stake by 1,219% in Q1 2026, buying an estimated $13.9M and bringing the position to 3,566,504 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2696.

Citadel Advisors first reported a position in CATX in Q4 2013 and has held it in 38 quarters since. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Citadel Advisors held 3,566,504 shares of Perspective Therapeutics worth $14.9M as of Q1 2026.
  • Citadel Advisors bought 3,296,013 Perspective Therapeutics shares in Q1 2026, an estimated $13.9M.
  • Perspective Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2696 holding.
  • Citadel Advisors first reported a position in Perspective Therapeutics in Q4 2013 and has held it in 38 quarters since.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.